Print

Denator AB Successfully Completes a 25.5 Million SEK Financing Round With Novo Seeds & Almi Invest as New Investors  
3/26/2012 8:13:54 AM

Gothenburg, Sweden – Denator AB today announced that the company has successfully completed a sixth round of financing, raising 25.5 million SEK (2,75 MEuro). Major contributions came from new investors, Novo Seeds, the early stage investment group of Novo A/S, and the venture capital company, Almi Invest. Existing investors also participated in this round of financing.

In conjunction with the investment, Søren Møller, Managing Investment Director at Novo Seeds, will join the Board of Directors. Mr. Møller explained the background to the Novo Seeds decision: “We are very pleased to co-lead this round with Almi Invest. We believe that Denator’s innovative heat-stabilization technology offer significant value to protein researchers in important areas such as neurodegenerative diseases and cancer. This is Novo Seeds’ first device investment and confirms our continued interest in funding innovative science and entrepreneurship throughout Scandinavia.”

Olof Sköld, CEO at Denator, continued: "We are extremely happy to close this 25,5 million SEK investment and wish to thank our existing investors who have continuously shown their commitment. We also welcome Novo Seeds and Almi Invest to Denator. This funding is an important milestone in our commercial development, and will enable us to strengthen our product development to meet the need our customers and continue our market expansion. We will benefit greatly from the additional resources and experience from our new investors."

About Denator

Denator AB is a privately held biotech company based in Gothenburg, Sweden. Denator develops and markets products that stabilize biological tissues and fluids from the moment of sampling. Stabilization and standardization of sampling processes upstream significantly enhances the quality of data obtained from analytical techniques used downstream. Based upon the company’s proprietary heat inactivation technology platform, Denator is developing solutions that enable scientists to stop sample degradation instantly and so maintain the stability of sample components throughout the analytical workflow.

For more information, please contact:

Olof Sköld

CEO

Denator AB

E-mail: olof@denator.com

Tel.: +46 31 41 28 90

Fax.: +46 31 41 28 40


//-->